Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944085 | 0.82 | NAMPT (0.33) | NAMPTVNN1SPR | |
| SCHEMBL14595273 | 0.79 | POLB (0.31) | — | |
| SCHEMBL25698959 | 0.77 | SPR (0.33) | NAMPTVNN1SPR | |
| SCHEMBL14595101 | 0.75 | GPR119 (0.33) | — | |
| SCHEMBL14595469 | 0.71 | HPGD (0.33) | — | |
| SCHEMBL14595370 | 0.71 | — | — | |
| SCHEMBL12142009 | 0.71 | CPN1 (0.33) | — | |
| SCHEMBL19014554 | 0.70 | POLB (0.47) | NAMPTVNN1SPR | |
| SCHEMBL7860329 | 0.69 | EPHX2 (0.46) | NAMPTSPR | |
| SCHEMBL11982547 | 0.69 | CYP2D6 (0.33) | NAMPTSPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | NAMPT 2637/4885VNN1 4016/4885SPR 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.